Maze Therapeutics (MAZE) Competitors $16.45 -1.19 (-6.75%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock MAZE vs. MOR, ALVO, CPRX, MIRM, ARWR, RARE, AMRX, OGN, GMTX, and IBRXShould you be buying Maze Therapeutics stock or one of its competitors? The main competitors of Maze Therapeutics include MorphoSys (MOR), Alvotech (ALVO), Catalyst Pharmaceuticals (CPRX), Mirum Pharmaceuticals (MIRM), Arrowhead Pharmaceuticals (ARWR), Ultragenyx Pharmaceutical (RARE), Amneal Pharmaceuticals (AMRX), Organon & Co. (OGN), Gemini Therapeutics (GMTX), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry. Maze Therapeutics vs. Its Competitors MorphoSys Alvotech Catalyst Pharmaceuticals Mirum Pharmaceuticals Arrowhead Pharmaceuticals Ultragenyx Pharmaceutical Amneal Pharmaceuticals Organon & Co. Gemini Therapeutics ImmunityBio Maze Therapeutics (NASDAQ:MAZE) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation. Do insiders & institutionals believe in MAZE or MOR? 18.4% of MorphoSys shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is MAZE or MOR more profitable? Maze Therapeutics has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Maze Therapeutics' return on equity of 0.00% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets Maze TherapeuticsN/A N/A N/A MorphoSys -226.79%-694.31%-22.55% Does the media favor MAZE or MOR? In the previous week, Maze Therapeutics had 9 more articles in the media than MorphoSys. MarketBeat recorded 9 mentions for Maze Therapeutics and 0 mentions for MorphoSys. Maze Therapeutics' average media sentiment score of 0.38 beat MorphoSys' score of 0.00 indicating that Maze Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Maze Therapeutics Neutral MorphoSys Neutral Do analysts recommend MAZE or MOR? Maze Therapeutics currently has a consensus target price of $25.60, indicating a potential upside of 55.62%. Given Maze Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Maze Therapeutics is more favorable than MorphoSys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maze Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher valuation & earnings, MAZE or MOR? Maze Therapeutics has higher earnings, but lower revenue than MorphoSys. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMaze Therapeutics$167.50M4.30$52.23MN/AN/AMorphoSys$238.28M11.99-$205.35M-$3.48-5.45 SummaryMaze Therapeutics beats MorphoSys on 10 of the 14 factors compared between the two stocks. Get Maze Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MAZE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MAZE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MAZE vs. The Competition Export to ExcelMetricMaze TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$772.58M$3.06B$5.70B$9.48BDividend YieldN/A2.37%4.59%3.99%P/E RatioN/A20.7327.9019.95Price / Sales4.30321.07442.18102.66Price / Cash115.2243.2336.5558.97Price / Book-2.318.308.635.90Net Income$52.23M-$55.19M$3.24B$258.42M7 Day Performance-3.58%5.07%3.22%1.94%1 Month Performance59.24%17.61%10.72%12.02%1 Year PerformanceN/A7.03%34.94%20.81% Maze Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MAZEMaze TherapeuticsN/A$16.45-6.7%$25.60+55.6%N/A$772.58M$167.50M0.00121News CoverageAnalyst ForecastMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730ALVOAlvotech2.8765 of 5 stars$8.63-1.1%$16.00+85.4%-22.4%$2.63B$491.98M23.321,032CPRXCatalyst Pharmaceuticals4.9134 of 5 stars$21.03-2.0%$32.83+56.1%+22.8%$2.62B$534.65M13.3980News CoveragePositive NewsMIRMMirum Pharmaceuticals3.9526 of 5 stars$51.93-1.5%$65.50+26.1%+32.0%$2.61B$336.89M-32.25140ARWRArrowhead Pharmaceuticals3.879 of 5 stars$16.76-11.1%$43.71+160.8%-44.7%$2.60B$3.55M-11.97400RAREUltragenyx Pharmaceutical4.3469 of 5 stars$26.31-4.0%$83.64+217.9%-38.0%$2.59B$590.69M-4.471,294Upcoming EarningsGap DownHigh Trading VolumeAMRXAmneal Pharmaceuticals3.2894 of 5 stars$7.97-3.3%$11.60+45.5%+8.6%$2.58B$2.83B-199.208,100OGNOrganon & Co.4.7622 of 5 stars$9.46-1.9%$18.00+90.3%-53.0%$2.51B$6.40B3.284,000GMTXGemini TherapeuticsN/A$57.770.0%N/A+32.2%$2.50BN/A-57.7730High Trading VolumeIBRXImmunityBio2.0236 of 5 stars$2.75-2.8%$12.25+345.5%-47.1%$2.50B$14.74M-4.74590 Related Companies and Tools Related Companies MorphoSys Competitors Alvotech Competitors Catalyst Pharmaceuticals Competitors Mirum Pharmaceuticals Competitors Arrowhead Pharmaceuticals Competitors Ultragenyx Pharmaceutical Competitors Amneal Pharmaceuticals Competitors Organon & Co. Competitors Gemini Therapeutics Competitors ImmunityBio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MAZE) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredBitcoin Beats Gold — But This Coin Could Beat Them BothBitcoin just hit a record high—but it’s not the top crypto play right now. Crypto analyst Juan Villaverde, ...Weiss Ratings | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maze Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maze Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
